FORE Biotherapeutics vs Nucleai
FORE Biotherapeutics vs Nucleai, compared side by side on 21 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: FORE Biotherapeutics is on 56/100 and Nucleai on 63/100.
Where each one leads
FORE Biotherapeutics
- domain rating: 33/100 against 29/100
- headcount growth: +8.2% against -7.0%
- funding raised: $232M against $58.5M
Nucleai
- our overall score: 63/100 against 56/100
- agent readiness: 42/100 against 37/100
- LinkedIn following: 18,902 against 4,584
At a glance
| Measure | FORE Biotherapeutics | Nucleai |
|---|---|---|
| What it is | Precision oncology company developing cancer therapies guided by proprietary functional genomics. | AI-powered spatial biology platform for precision medicine and drug development. |
| Category | Healthcare, Drug Development, Genomics, Next Generation Sequencing | Healthcare, Oncology, Pharmaceutical, HealthTech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2011 | 2018 |
| Headquarters | Philadelphia, United States | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | FORE Biotherapeutics | Nucleai |
|---|---|---|
| Employees | 56 | 66 |
| Headcount growthLast 12 months | +8.2% | -7.0% |
| Total funding | $232M | $58.5M |
| Latest round | Series D-2 Extension | Series B |
| Valuation | $75.0M | Not published |
| LinkedIn followers | 4,584 | 18,902 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | FORE Biotherapeutics | Nucleai |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 56/100 | 63/100 |
| Traction | 58/100 | 57/100 |
| Team | 70/100 | 70/100 |
| Community | Not published | 8/100 |
| Search visibility | 38/100 | 31/100 |
| Quality | 55/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (37/100) | D (42/100) |
| Domain ratingLink authority, 0-100 | 33/100 | 29/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | FORE Biotherapeutics | Nucleai |
|---|---|---|
| CMS | WordPress | WordPress |
| Frameworks | Jquery | Jquery |
| Analytics | Not detected | Google Tag Manager, Linkedin Insight, Facebook Pixel |
| Support stack | Not detected | HubSpot |
FORE Biotherapeutics vs Nucleai: common questions
Which is better, FORE Biotherapeutics or Nucleai?
On our 0-100 score Nucleai rates higher (63/100 against 56/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 21 data points above: read the rows that match what you are buying for.
How do FORE Biotherapeutics and Nucleai compare on the numbers?
FORE Biotherapeutics leads on domain rating (33/100 against 29/100), headcount growth (+8.2% against -7.0%), funding raised ($232M against $58.5M). Nucleai leads on our overall score (63/100 against 56/100), agent readiness (42/100 against 37/100), LinkedIn following (18,902 against 4,584).
Read the full FORE Biotherapeutics review and pricing or the Nucleai review and pricing. You can also browse other FORE Biotherapeutics alternatives we track.